Asymptomatic Testicular Atrophy: Causes and Management

Asymptomatic testicular atrophy (volume <12 mL) requires a systematic diagnostic workup to identify the underlying etiology—ranging from congenital cryptorchidism to iatrogenic injury—and management must prioritize cancer risk stratification, fertility preservation, and hormonal assessment rather than immediate intervention. 1, 2

Definition and Diagnostic Threshold

Testicular volume below 12 mL definitively indicates atrophy when accompanied by clinical context including elevated FSH, history of cryptorchidism, or impaired spermatogenesis. 1, 2
The diagnosis is not made by volume measurement alone but requires comprehensive evaluation including hormonal assessment, ultrasound characteristics, and patient history. 2
Use the Lambert formula (Length × Width × Height × 0.71) for volume calculation, as the traditional ellipsoid formula (0.52 coefficient) systematically underestimates volume by 20-30% and may lead to misclassification. 1

Etiologies of Bilateral Asymptomatic Testicular Atrophy

Primary Testicular Dysfunction (Hypergonadotropic Hypogonadism)

Congenital/Developmental:

Klinefelter syndrome (47,XXY) is the most common genetic cause of primary testicular failure with volume <12 mL and elevated FSH. 1
Bilateral cryptorchidism, especially when uncorrected or surgically corrected after puberty, markedly increases atrophy risk. 1, 3
Myotonic dystrophy (types I and II) presents with painless bilateral testicular atrophy due to primary gonadal failure. 1

Acquired:

Prior chemotherapy or pelvic/testicular radiation causes irreversible testicular shrinkage. 1
Autoimmune orchitis may affect both testes with relatively painless atrophic progression. 1
Sickle-cell disease with recurrent vaso-occlusive crises leads to chronic testicular hypoperfusion and atrophy. 1

Secondary Testicular Dysfunction (Hypogonadotropic Hypogonadism)

Chronic opioid use suppresses GnRH secretion, resulting in low gonadotropins and bilateral testicular atrophy. 1
Anabolic-steroid or exogenous testosterone use causes complete suppression of spermatogenesis and can produce persistent atrophy for months to years after cessation. 1
Hyperprolactinemia from pituitary adenoma or prolactin-raising medications leads to secondary hypogonadism and testicular shrinkage. 1
Kallmann syndrome or idiopathic hypogonadotropic hypogonadism present with low LH/FSH and small testes. 1

Systemic Conditions

Type 2 diabetes mellitus/metabolic syndrome is linked to functional hypogonadism and reduced testicular volume. 1
Chronic liver disease (cirrhosis) contributes to secondary hypogonadism and testicular atrophy. 1
Chronic kidney disease is associated with decreased testosterone production and testicular size. 1
HIV infection can cause both primary and secondary gonadal dysfunction leading to atrophy. 1

Iatrogenic/Mechanical Causes

Inguinal hernia repair causes testicular atrophy in 0.3-5% of cases due to thrombosis of spermatic cord veins from surgical trauma, particularly with overzealous dissection of the distal hernia sac. 4, 5
Chronic incarcerated inguinal hernia compresses testicular vessels, leading to ischemic orchitis and subsequent atrophy. 6
Testicular torsion (intrauterine or prepuberal) causes primary and secondary testicular atrophy through ischemia. 7
Orchiopexy for high undescended testis frequently results in secondary testicular atrophy. 7

Diagnostic Workup

Laboratory Evaluation

Obtain morning serum FSH, LH, and total testosterone between 08:00-10:00 hours on two separate occasions to differentiate primary from secondary hypogonadism. 1, 2
When total testosterone is low, measure free testosterone by equilibrium dialysis together with sex-hormone-binding globulin (SHBG) to differentiate true hypogonadism from alterations in binding proteins. 1
Perform karyotype analysis when FSH is elevated and testicular volume is <12 mL to screen for Klinefelter syndrome. 1
Measure serum prolactin to exclude hyperprolactinemia as a cause of secondary hypogonadism. 1
Obtain tumor markers (AFP, β-HCG, LDH) if malignancy is suspected based on ultrasound findings or clinical context. 8, 2

Interpretation of Hormonal Patterns:

Elevated FSH (>7.6 IU/L) with testicular volume at 12 mL threshold indicates reduced testicular reserve and impaired spermatogenic capacity. 1
Elevated LH suggests primary testicular failure. 1
Low or normal LH points toward secondary (hypothalamic-pituitary) dysfunction. 1

Imaging

Conduct scrotal ultrasound with high-frequency probes (>10 MHz) to quantify testicular volume using standardized three-dimensional measurements (length, width, height), assess architecture, and rule out masses. 1, 2
Volumes <12 mL are considered definitively atrophic. 1, 2
Size discrepancy between testes >2 mL or 20% warrants further evaluation to exclude pathology, regardless of absolute volume. 1

Critical History Elements

Prior undescended testes (cryptorchidism) dramatically raises the risk of atrophy and testicular cancer. 1, 3
Use of anabolic steroids, testosterone, opioids, or glucocorticoids should be elicited as potential etiologic factors. 1
History of chemotherapy or radiation to the pelvis/testes warrants focused evaluation. 1
Previous inguinal or scrotal surgery (hernia repair, orchiopexy) increases risk of iatrogenic atrophy. 4, 5
Family history of Klinefelter syndrome or other hypogonadal disorders is a pertinent clue. 1
Presence of systemic disease (diabetes, liver disease, chronic infection) should be documented. 1

Cancer Risk Stratification

High-Risk Scenarios Requiring Contralateral Testicular Biopsy

The following criteria mandate consideration of testicular biopsy:

Age <30-40 years with testicular volume <12 mL carries a ≥34% risk of testicular intraepithelial neoplasia (TIN) in the contralateral testis if testicular cancer is present. 9, 1, 2
History of cryptorchidism combined with volume <12 mL, regardless of cancer diagnosis, is an indication for contralateral testicular biopsy. 9, 1, 2
If TIN is left untreated, approximately 70% progress to invasive testicular cancer within 7 years. 9, 1

Surveillance Recommendations

Teach testicular self-examination to all patients with testicular atrophy given 3.6-7.4 times higher risk of germ cell tumors. 1, 8, 2
Routine follow-up should include annual physical examination with attention to the contralateral testis. 2

Fertility Assessment and Preservation

Semen Analysis

Testicular volume <12 mL strongly correlates with impaired spermatogenesis, lower total sperm count, and reduced sperm concentration. 1, 2
Perform semen analysis to assess sperm concentration, motility, and morphology, as testicular volume alone does not reliably predict fertility. 1, 2
Repeat semen analysis every 6-12 months to monitor declining parameters, as single analyses can be misleading due to natural variability. 1

Fertility Preservation

Discuss sperm banking before any surgical intervention, radiotherapy, or initiation of testosterone therapy that might affect fertility. 8, 2
Never start testosterone replacement without first clarifying the patient's fertility intentions, because exogenous testosterone suppresses the hypothalamic-pituitary-gonadal axis and can cause complete azoospermia that may take months to years to recover. 1

Treatment Strategies

Hormonal Management

Testosterone replacement should not be started without first clarifying fertility intentions, as exogenous testosterone can cause azoospermia. 1
In cases of bilateral testicular atrophy with confirmed hypogonadism, testosterone replacement therapy may be indicated after fertility preservation is addressed. 8
Periodic testosterone monitoring is necessary in patients with bilateral atrophy or post-radiation. 2

Surgical Considerations

In adults with unilateral undescended testis and atrophy, orchidopexy may be offered to preserve androgen production and fertility potential. 8
If the contralateral testis is normal, orchiectomy may be considered due to the increased risk of testicular cancer in the undescended atrophic testis. 8
Testis-sparing surgery (TSS) may be offered in highly selected patients with masses <2 cm with equivocal ultrasound/physical exam findings and negative tumor markers, but patients must be counseled regarding higher risk of local recurrence compared to radical orchiectomy. 9, 2

Management of Specific Etiologies

Discontinue anabolic steroids or exogenous testosterone if identified as the cause; recovery of spermatogenesis may take months to years. 1
Treat hyperprolactinemia with dopamine agonists if pituitary adenoma is identified. 1
Address systemic conditions (diabetes, liver disease, chronic kidney disease) to optimize testicular function. 1

Common Pitfalls and How to Avoid Them

Failing to consider fertility preservation before definitive treatment is the most common error; always discuss sperm banking before surgery or testosterone therapy. 8, 2
Overlooking the increased risk of testicular cancer in patients with atrophic testes, particularly those with a history of cryptorchidism; ensure annual surveillance and teach self-examination. 8, 2
Starting testosterone replacement without hormonal workup or fertility counseling can cause irreversible azoospermia; always obtain FSH, LH, and testosterone levels first. 1
Using incorrect volume calculation formulas (0.52 ellipsoid formula) leads to underestimation of volume and inappropriate classification; always use the Lambert formula (0.71 coefficient). 1
Failing to obtain karyotype in young men with elevated FSH and small testes misses Klinefelter syndrome diagnosis; karyotype is mandatory in this setting. 1

Long-Term Monitoring

Regular monitoring of hormone levels and testicular volume is recommended to detect progression or development of complications. 8
Long-term follow-up is necessary to monitor for late complications including hypogonadism and malignancy. 8
Repeat semen analysis every 6-12 months if fertility is a concern, as parameters may decline over time. 1

What are the causes and recommended management for asymptomatic testicular atrophy?

Help us tailor your experience